PaxMedica is a clinical-stage biopharmaceutical company developing innovative treatments for unmet needs in neurodevelopmental disorders, including Autism Spectrum Disorder (ASD) and Fragile X-associated tremor/ataxia (FXTAS).
Our focus is on anti-purinergic therapies (APT), i.e. therapies that target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (ATP), the main energy molecule in all living cells.
Our lead programs PAX-101 and PAX-102 utilize our proprietary source of suramin sodium, a broadly acting APT that has been around for over 100 years. Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT) or African Sleeping Sickness, we are also developing PAX-101 as a treatment for HAT. We expect that an FDA approval in HAT would grant PaxMedica with a Priority Review Voucher (PRV).